Jingwu Zang, I-Mab acting CEO

I-Mab ex­pands man­u­fac­tur­ing for mul­ti­ple myelo­ma an­ti­body; Gran­ules is­sued 'mi­nor ob­ser­va­tion­s' af­ter in­spec­tion

Chi­na-based bio­phar­ma I-Mab has land­ed a part­ner­ship with Shang­hai’s Hangzhou Qiantang New Area to man­u­fac­ture drugs lo­cal­ly and speed up the com­pa­ny’s path to­ward com­mer­cial­iza­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.